HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB:RBCC) has promised to double its efforts to make certain people addicted to opioids have access to treatment after a major university study showed nearly 80 percent are shut out of the system.
The study, conducted by the prestigious Johns Hopkins Bloomberg School of Public Health, revealed only 22 percent of opioid addicts received any kind of treatment between 2009 and 2013 (the years of the survey). The rest received no help of any kind.
A major factor was the lack of treatment capacity – an earlier, related study confirmed the Johns Hopkins’ findings that most cities and towns had no facilities to provide help, meaning that even if patients wanted treatment, there was nowhere for them to go.
As a result, the study concluded that up to one million opioid addicts needing help were left to their own devices to overcome their addiction.
“One million people being shut out is not acceptable,” said RBCC CEO Kimberly Palmer. “We want to end addiction. We’ve worked to make the anti-addiction drug Naltrexone readily available and to develop practical, low-cost treatment programs. We’ve opened channels and will aggressively explore all options – partnerships, joint ventures, investments – to get people help. This is not just about good business, but also about being a good neighbor to those in need.”
The Centers for Disease Control said heroin use has surged 63 percent since 2005 and 45 percent of those addicted to heroin are also addicted to prescription opioids. Johns Hopkins found deaths from pain killer prescription overdoses doubled over the study period and heroin overdose deaths quadrupled.
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
